Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda

This study has been completed.
Sponsor:
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00639938
First received: March 18, 2008
Last updated: April 1, 2008
Last verified: March 2008
  Purpose

The increase in pediatric HIV infection has a substantial impact on childhood mortality in the developing world. A number of recent studies suggest that as many as half or more of mother-to-child HIV transmissions in developing countries occur in late pregnancy or during labor and delivery. Interventions targeted during the perinatal period have shown to be effective and to have a significant impact in reducing transmission. The purpose of this study is to investigate the effectiveness of nevirapine (NVP) plus immunoprophylaxis or extended NVP dosing regimens in HIV-infected pregnant women and their infants during the perinatal period.


Condition Intervention Phase
HIV Infections
Drug: Nevirapine
Drug: HIV immune globulin solution
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Prevention
Official Title: A Phase III Randomized Clinical Trial of the Standard Two Dose Nevirapine (NVP) Regimen With the Addition of HIV Immune Globulin(HIVIGLOB) or Extended Infant NVP Dosing Compared With the Standard NVP Regimen Alone for the Prevention of Maternal-Infant HIV Transmission in Uganda

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Rate of HIV infection in infants born to study participants in each arm of the study [ Time Frame: At Birth, Weeks 2, 6, and 14, and Months 6, 12, and 18 ] [ Designated as safety issue: Yes ]
  • Safety and tolerance of HIVIGLOB given to pregnant women at 36-37 weeks gestation and neonates at birth in combination with NVP and of NVP alone [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Rate of immunologic progression in HIV-infected infants in each arm [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
  • Infant mortality [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
  • Maternal plasma HIV RNA levels at delivery [ Time Frame: At Birth ] [ Designated as safety issue: Yes ]
  • Immunologic, virologic, and pharmacologic factors [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

Enrollment: 722
Study Start Date: July 2004
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1

Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor

Infant dosing regimen: Single dose of 2 mg/kg NVP taken orally within the first week after delivery

Drug: Nevirapine
200 mg Nevirapine tablet
Other Name: NVP Viramune
Experimental: 2

Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor

Infant dosing regimen: 2 mg/kg NVP taken orally within the first week after delivery and 5 mg NVP taken orally daily from Day 8 through Week 6

Drug: Nevirapine
200 mg Nevirapine tablet
Other Name: NVP Viramune
Experimental: 3

Mother dosing regimen: Single 12 gm intravenous dose of HIVIGLOB at 36 - 37 weeks gestation and 200 mg NVP taken orally at onset of labor

Infant dosing regimen: Single 1.2 gm intravenous dose HIVIGLOB within 18 hours of birth and 2 mg/kg NVP taken orally within the first week after delivery

Drug: Nevirapine
200 mg Nevirapine tablet
Other Name: NVP Viramune
Drug: HIV immune globulin solution
5% intravenous HIV immune globulin solution
Other Name: HIVIGLOB

Detailed Description:

There is an urgent need to find safe, effective means of preventing mother-to-child-transmission (MTCT) of HIV that can be used in developing countries. One of the greatest obstacles to prevention in these areas remains HIV transmission through breast milk. The primary purpose of this trial is to determine if nevirapine (NVP) plus immunoprophylaxis (by intravenous HIV immune globulin [HIVIGLOB]) or extended NVP dosing of the neonate during the perinatal period can safely and effectively reduce the risk of peripartum or early breastfeeding-related HIV MTCT.

This study will last 11-18 weeks for each mother and 18 months for each infant. HIV-infected pregnant women will be randomly assigned to one of three arms. Participants in Arm 1 will receive a single dose of 200 mg NVP orally at the onset of labor. Infants in Arm 1 will receive a single dose of 2 mg/kg NVP orally within the first week after delivery. Arm 2 participants will receive a single dose of 200 mg NVP orally at the onset of labor. Infants in Arm 2 will receive 2 mg/kg NVP orally within the first week after delivery and 5 mg NVP taken orally daily from Day 8 through Week 6. Arm 3 participants will receive a 12 gm intravenous dose of HIVIGLOB at 36-37 weeks gestation and 200 mg NVP orally at the onset of labor. Infants in Arm 3 will receive a single 1.2 gm intravenous dose HIVIGLOB within 18 hours of birth and 2 mg/kg NVP orally within the first week after delivery.

There will be five or six study visits for pregnant participants. A targeted medical history, physical examination, and blood collection will occur at all visits. After birth, there will be 11 study visits for infants in Arms 1 and 2 and 12 study visits for infants in Arm 3. Medical history and a targeted physical exam will occur at all visits. Blood collection will occur at some visits.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pregnant between 32-36 weeks estimated gestation
  • HIV Infected
  • Intent to breastfeed infant
  • Certain laboratory criteria. More information on this criterion can be found in the protocol.

Exclusion Criteria:

  • Sensitivity to immune globulin preparations or any benzodiazepine
  • Clinically significant disease, as determined by the investigator, that would compromise the ability of the participant to complete the study requirements
  • Currently receiving antiretroviral therapy (other than the intrapartum NVP or other peripartum regimens)
  • Participation in any HIV vaccine trials
  • History of cytotoxic chemotherapy within one month of study entry
  • Uncontrolled hypertension
  • Chronic alcohol or illicit drug use
  • History of non-compliance with visits or medication
  • Women who become pregnant again during study follow-up will not be eligible for re-enrollment in the trial
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00639938

Sponsors and Collaborators
Investigators
Principal Investigator: Brooks Jackson, MD Johns Hopkins School of Medicine
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Brooks Jackson, MD, Johns Hopkins School of Medicine
ClinicalTrials.gov Identifier: NCT00639938     History of Changes
Other Study ID Numbers: R01-AI-34235
Study First Received: March 18, 2008
Last Updated: April 1, 2008
Health Authority: United States: Food and Drug Administration
NIAID DSMB

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Pregnancy, High-Risk
HIV Seronegativity

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Antibodies
Immunoglobulins
Nevirapine
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 23, 2014